Contains MicroLactin™ - concentrated bioactive milk proteins, obtained through the patented process. The product has been manufactured using high quality pure raw materials and the technology that ensures all their beneficial properties intact, in strict compliance with GMP and TÜV regulations.
It would be great if milk, which you add to your cereals in the morning, not only contained essential nutrients but also would be able to decrease joint pain and stiffness, normalize blood pressure and cholesterol, and improve your athletic performance!
The unique Santegra®’s product Arthromil™ makes this dream true!
Milk is rich in vital nutrients and scientific research has also uncovered the fact that milk contains micronutrients that have unique and useful biological activity. In a normal serving of milk, however, this activity occurs at a very low level. Stolle Milk Biologics, Inc. scientists invented innovative technology, which involves sophisticated processes that enhance the expression of powerful "micronutrients" found naturally in cows' milk.
Arthromil™ contains MicroLactin™ - a revolutionary new dietary supplement clinically proven to promote healthy joint function.
The active ingredients in MicroLactin™ are concentrated milk proteins. These proteins are found naturally in cow's milk and are comprised of unique antibodies and other bioactive micronutrients. Using a patented process that isolates and concentrates these natural proteins in sufficient quantities, MicroLactin™ can be encapsulated.
But MicroLactin™ has much more benefits other than joint care! Clinical trials have shown the benefit of the active ingredients in MicroLactin™ in maintaining blood pressure and healthy cholesterol levels. There are potential benefits in sports recovery that is supported by a clinical trial showing improved recovery times in long distance runners. Finally, MicroLactin™ is also rich in antibodies, which may play a role in promoting good intestinal health
MicroLactin™ is created by Stolle Milk Biologics, Inc. (SMBI) - a science-based company that develops and markets proprietary milk-based dietary supplements. SMBI's innovative technology involves sophisticated processes that enhance the expression of powerful "micronutrients" found naturally in cows' milk. These micronutrients are comprised of unique antibodies and other potent immune factors that are isolated from the milk and processed into various health-enhancing supplement products.
Through more than 30 years of research and development, SMBI has verified the safety and efficacy of these novel micronutrients. During this time, 16 clinical trials have been conducted involving more than 700 subjects. Additionally, the company conducted an extensive survey of consumers using its products and documented over 8,000 case histories. These studies have demonstrated the significant health benefits of SMBI's milk micronutrients including: improving joint health, promoting healthy cholesterol, supporting normal blood pressure and improving muscle recovery after exercise.
To insure strict adherence to world-class dairy management standards, SMBI manufactures its milk micronutrients in New Zealand under the auspices of the New Zealand Dairy Board. All SMBI products are produced from pasture-fed dairy cows that are antibiotic and hormone free.
A more concentrated form of the product, called MicroLactin™, has been developed for the U.S. supplement market and is being marketed by Humanetics Corporation.
MicroLactin™ - a revolutionary new dietary supplement clinically proven to promote healthy joint function.
Per 1 tablet:
MicroLactin™ (Milk Protein Concentrate) – 500 mg
For adults: take 4 tablets with a large glass of water twice daily for the first 7-10 days and 2 tablets with a large glass of water twice daily thereafter as a dietary supplement.
Individuals with allergy to cow's milk protein should avoid taking MicroLactin™. Milk proteins in MicroLactin™ may interfere with the activity of tetracycline-type antibiotics.
To date, MicroLactin™ has only been clinically tested in adults. Use by individuals under the age of 20 should be done under the care of a health care provider.
Milk is a complex substance consisting of fat, casein, whey proteins (which include IgG antibodies), milk sugars, vitamins, and minerals. Milk has traditionally been viewed only from a nutritional standpoint. We all know that the macronutrients in milk (calcium, vitamins, proteins, etc.) can benefit our health. However, SMBI’s research has identified that milk also contains micronutrients that have unique and useful biological activity. However, this activity occurs at a very low level in normally processed milk.
Over the past 30 years SMBI researchers have discovered that stimulation of a cow’s immune system can enhance the expression of the many biologically useful micronutrients that naturally occur in milk. This work is built upon the theories and work of Dr. William Petersen, Professor of Dairy Science at the University of Minnesota. It was Dr. Petersen who pioneered the concept of "immune milk" in the 1950’s. Petersen confirmed the health benefits of milk from cows treated with special immune stimulants. Petersen demonstrated that the cow’s natural process of creating antibodies to the antigens present in the immune stimulant was passed to the milk and could benefit anyone who consumed the milk. It was SMBI that put forth the money, effort and scientific methods necessary to understand the "how and why" of this phenomenon. SMBI has spent years determining both how to enhance the expression of the micronutrients in milk and which fractions of milk contain the micronutrients. Furthermore, SMBI has developed commercial-scale processes to separate and manufacture the micronutrients.
SMBI’s research has led to the development of a potent fraction of milk called MicroLactin™. This fraction contains the same biological activity of intact milk at a much lower dose. It is anticipated that even further breakthroughs will be made and even more potent, bioactive fractions will soon be made available to consumers.
8,000 Case Histories Reveal the Power of Milk Micronutrients
Continuously, from 1960 to 1996, SMBI distributed, free of charge, a powdered drink containing milk micronutrients to consumers around its headquarters in Cincinnati, Ohio. Consumers were asked to complete and return survey forms to the company. This 35 year study, which documented over 8,000 case histories, has become known as the Ohio Survey.
The Ohio Survey is a landmark study of the safety and efficacy of SMBI’s milk micronutrients. We know of no other dietary supplement with such extensive documentation of use and effects. The intent of the Survey was to gather a large database of consumer usage to understand both the safety and benefits of daily consumption of the milk micronutrients. Data gathered from participants included basic background information on sex, age, weight, height, doctor’s or subject’s assessment of health status including any known ailments, and a general health history with documentation of any medications. Participants were asked to consume 45 grams of powder containing the special milk micronutrients, which was typically reconstituted with water and consumed once daily as a beverage. Participants were asked to periodically complete survey forms to document their health status and any side effects.
During the first fifteen years of the survey the company documented 3,545 case histories. The results showed that the product was well tolerated and, more importantly, that the users perceived significant health benefits. In the early 1990’s SMBI computerized the database and during the last five years of the Survey, documented another 4,867 consumer experiences with the supplement. The accompanying table shows the total number of participants, their reported conditions at the beginning of the survey and the percentage that reported improvement. As can be seen by the data, 73.5% of all consumers reported an improvement in their overall health.
SMBI used the results of the Ohio Survey to steer its clinical research efforts. Since the Survey was not a controlled clinical trial, the company took the further step of conducting a multitude of controlled clinical trials. These human trials, conducted by independent research organizations under controlled circumstances, confirmed many of the findings in the Ohio Survey.
In an effort to validate the dramatic findings of the Ohio Survey, SMBI scientists designed and conducted a multitude of clinical trials in various health areas. Since 1975, the company has completed 16 well-controlled trials. These studies were all conducted by independent clinical research organization or at major research universities. In total, over 700 subjects have been studied and documented.
This research supported the findings of the Ohio Survey. The strength and validity of the results in these clinical trials have supported the issue of more than 200 worldwide patents on the uses of SMBI’s micronutrient technology.
The Effects of Milk Protein Concentrate on the Symptoms of Osteoarthritis in Adults: An Exploratory, Randomized, Double-Blind, Placebo-Controlled Trial
John L Zenk, MD, Tami R Helmer, MD, and Michael A Kuskowski, PhD
Background: Reconstituted hyperimmune milk product has been shown to have anti-inflammatory qualities, prompting further research into its use for the relief of osteoarthritis symptoms. A concentrated form of this milk product, milk protein concentrate (MPC), contains the high-molecular-weight and low-molecular-weight components present in the reconstituted milk product.
Objective: The purpose of this exploratory study was to assess the effects of MPC on the symptoms of osteoarthritis in adults.
Methods: Patients aged > 19 years with physician-diagnosed osteoarthritis with daily joint pain, stiffness, and immobility were eligible. This was a prospective, randomized, double-blind, placebo-controlled trial lasting 6 weeks and having 3 treatment arms: MPC 2000 mg BID, glucosamine sulfate 500 mg TID, and placebo. Osteoarthritis symptoms were assessed using the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index.
Results: Forty-two participants were enrolled (8 men, 34 women; mean age 59 years [range 34-86 years]); 35 patients (5 men, 30 women) completed the study. Due to significant baseline differences in 3 (stiffness, activities, and total) of the 4 (pain, stiffness, activities, and total) WOMAC Osteoarthritis Index scores in the placebo group compared with the MPC- and glucosamine sulfate-treated groups (P < 0.05), the results of this study were restricted to the analysis of intragroup performance from baseline to the completion of the study. The results showed significant improvement from baseline to week 6 for the MPC-treated group for all 4 scores (P < 0.005). In the glucosamine sulfate-treated group, a significant improvement was found in stiffness and total WOMAC Osteoarthritis Index scores from baseline to week 6 (P < 0.05 for both) but not in the pain or activities scores. In the placebo group, no significant changes were found in any of the WOMAC Osteoarthritis Index scores.
Conclusion: The results of this study indicate that MPC, when given at a dose of 2000 mg BID, was effective in relieving the symptoms of osteoarthritis, including joint pain, joint stiffness, and immobility, in this patient population1.
As principal investigator, Dr. Zenk recently conducted a double-blind clinical study to evaluate the effectiveness of MicroLactin™ for joint health. The results of the study reveal that MicroLactin™, when given in a dose of 2 grams twice daily, resulted in significant improvement in joint pain, stiffness, and activities of daily living.
In addition, MicroLactin™ was shown to be 33% better in relieving joint pain from daily activity when compared to Glucosamine. Due to its unique mechanism of action, Dr. Zenk believes that other joint support supplements, such as Glucosamine and Chondroitin, may work even better when taken with MicroLactin™. (1)
Cholesterol-Lowering Effect of Skim Milk from Immunized Cows in Hypercholesterolemic Patients
Alain Golay, Jean-Marc Ferrara, Jean-Pierre Felber, and Heinz Schneider
The effect of skim milk from cows immunized against a variety of human intestinal bacteria on serum cholesterol concentrations was examined in 11 patients with primary hypercholesterolemia in a 24 week, randomized, double-blind, placebo-controlled, crossover study. After a 4 week baseline period patients were treated for eight weeks either with skim milk from immunized cows (active) or with control skim milk (placebo) followed by an 8 week period with the treatment order reversed. Eight weeks of active treatment with skim milk from immunized cows reduced serum total cholesterol concentrations by 0.52-0.59 mmol/L (mean-SD: P<0.025), or 8%, LDL cholesterol by 0.16-0.59 mmol/L (NS), or 4% and the atherogenic index (total cholesterol/HDL cholesterol) by 0.42-1.85 (P<0.05), or 8%, compared with the placebo treatment. Reversal of the favorable development occurred upon cessation of active treatment. We conclude that daily supplementation of a normal diet with skim milk from immunized cows can result in a significant reduction of elevated blood cholesterol concentrations. (2)
Susan J Sharpe, Gregory D Gumble, and D Norman Sharpe
The plasma cholesterol-lowering and blood pressure effects of a skim milk powder (immune milk) produced from diary cows hyperimmunized with a multivalent bacterial vaccine were assessed in a double-blind crossover study of hypercholesterolemic subjects who consumed daily 90 g immune milk or a normal product. There was a significant reduction in plasma total and LDL cholesterol of 5.2% (95% CI 2.5, 7.9) and 7.4% (95% CI 4.1, 10.7), respectively, with 10 weeks of immune consumption compared with control, but no change in HDL cholesterol or triglycerides. A significant systolic and diastolic blood pressure-lowering effect (5 and 4 mm Hg, respectively) was also demonstrated. Thus, immune milk may be a useful adjunct in the dietary management of hypercholesterolemia and the mechanisms of its cholesterol-lowering and blood pressure effects warrant further study. (3)
A Multicenter, Double-blind, Placebo-controlled Study of Stolle Milk as Adjunct Therapy in Adult Rheumatoid Arthritis
Investigators included fourteen board-certified rheumatologists throughout U.S.A. The study was designed, monitored, and reported by Pharmaco, an Independent clinical research organization based in Austin, Texas; 1993
The study was designed to evaluate the safety and efficacy of Stolle milk powder compared with commercial (placebo) milk powder in 211 patients with adult rheumatoid arthritis. The dosage was 45 grams Stolle or control milk powder twice daily. Evaluation criteria included assessment of overall disease severity, joint counts, disability monitoring, duration of morning stiffness, consumption of arthritis medication, laboratory tests, and visual analog pain assessments.
Marked improvement was detected in Stolle milk patients with regard to joint counts, duration of morning stiffness, and visual analog pain scores.
Regarding side effects, no difference between Stolle milk and placebo groups and no clinically significant changes in laboratory test results or physical examinations were detected.
1. Zenk, et al, Current Therapeutic Research Vol. 63(7), and pp 430-442, Copyright 2002 by Excerpta Medica, Inc.
2. Golay, A., et. al. Cholesterol-Lowering Effect of Skim Milk from Immunized Cows in Hypercholesterolemic Patients. Am. J. Clin. Nutr. 52: 1014-1019; 1990.
3. Sharpe, S.J., et. al. Cholesterol-Lowering and Blood Pressure Effects of Immune Milk. Am. J. Clin. Nutr. 59: 929-934; 1994.